[{"id":"6a7737ea-7363-4409-b641-c11409e515ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT04181060","created_at":"2021-01-18T20:23:16.793Z","updated_at":"2025-02-25T12:37:29.255Z","phase":"Phase 3","brief_title":"Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer","source_id_and_acronym":"NCT04181060","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tagrisso (osimertinib) • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 12/28/2020","start_date":" 12/28/2020","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-24"},{"id":"229e5d3e-73c3-45a5-974b-b16c7567422e","acronym":"TARGET","url":"https://clinicaltrials.gov/study/NCT05526755","created_at":"2022-09-02T17:00:16.764Z","updated_at":"2024-07-02T16:34:25.955Z","phase":"Phase 2","brief_title":"A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)","source_id_and_acronym":"NCT05526755 - TARGET","lead_sponsor":"AstraZeneca","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 03/06/2023","start_date":" 03/06/2023","primary_txt":" Primary completion: 04/05/2029","primary_completion_date":" 04/05/2029","study_txt":" Completion: 04/05/2029","study_completion_date":" 04/05/2029","last_update_posted":"2024-06-14"},{"id":"66566ad0-5762-43b1-aaba-eb5e68316afa","acronym":"NCI-2019-05913","url":"https://clinicaltrials.gov/study/NCT04085315","created_at":"2021-01-18T19:59:58.628Z","updated_at":"2024-07-02T16:34:36.874Z","phase":"Phase 1","brief_title":"Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer","source_id_and_acronym":"NCT04085315 - NCI-2019-05913","lead_sponsor":"Collin Blakely","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR E709K • EGFR exon 19 insertion • EGFR H835L • EGFR L833V • EGFR V834L","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR E709K • EGFR exon 19 insertion • EGFR H835L • EGFR L833V • EGFR V834L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • alisertib (MLN8237)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 11/12/2019","start_date":" 11/12/2019","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-10"},{"id":"626349ae-5e92-4b7b-935d-204508ea15b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05546866","created_at":"2022-09-21T21:57:03.169Z","updated_at":"2024-07-02T16:35:00.447Z","phase":"Phase 2","brief_title":"Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm","source_id_and_acronym":"NCT05546866","lead_sponsor":"AstraZeneca","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 02/21/2023","start_date":" 02/21/2023","primary_txt":" Primary completion: 06/30/2029","primary_completion_date":" 06/30/2029","study_txt":" Completion: 06/30/2029","study_completion_date":" 06/30/2029","last_update_posted":"2024-05-29"},{"id":"93f98008-2763-4eb8-b3d9-f6477ef24b99","acronym":"FURMO-002","url":"https://clinicaltrials.gov/study/NCT05364073","created_at":"2022-05-06T18:55:07.280Z","updated_at":"2024-07-02T16:35:02.618Z","phase":"Phase 1","brief_title":"Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations","source_id_and_acronym":"NCT05364073 - FURMO-002","lead_sponsor":"ArriVent BioPharma, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 exon 20 insertion • EGFR G719X • EGFR S768I • EGFR G724S • HER-2 exon 23 mutation • EGFR R776C • EGFR V774M","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 exon 20 insertion • EGFR G719X • EGFR S768I • EGFR G724S • HER-2 exon 23 mutation • EGFR R776C • EGFR V774M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 06/30/2022","start_date":" 06/30/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-05-20"},{"id":"7fda6a16-7aec-4560-a322-7d0985c54708","acronym":"EXCLAIM-2","url":"https://clinicaltrials.gov/study/NCT04129502","created_at":"2021-01-18T20:10:25.140Z","updated_at":"2024-07-02T16:35:03.030Z","phase":"Phase 3","brief_title":"TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations","source_id_and_acronym":"NCT04129502 - EXCLAIM-2","lead_sponsor":"Takeda","biomarkers":" HER-2","pipe":" | ","alterations":" EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • pemetrexed • Exkivity (mobocertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 354","initiation":"Initiation: 01/10/2020","start_date":" 01/10/2020","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-05-17"},{"id":"63acc23b-8534-4603-8475-20ff97145f0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05805631","created_at":"2023-04-10T14:03:05.133Z","updated_at":"2024-07-02T16:35:06.695Z","phase":"Phase 2","brief_title":"Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC","source_id_and_acronym":"NCT05805631","lead_sponsor":"Taipei Veterans General Hospital, Taiwan","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • pemetrexed"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-05-01"},{"id":"f3aa5ebc-ff8a-48a1-8ade-20d99888b813","acronym":"","url":"https://clinicaltrials.gov/study/NCT05821933","created_at":"2023-04-20T14:03:56.574Z","updated_at":"2024-07-02T16:35:10.455Z","phase":"Phase 1/2","brief_title":"RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC","source_id_and_acronym":"NCT05821933","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR G719X • EGFR S768I • MET expression • EGFR exon 18 mutation","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR G719X • EGFR S768I • MET expression • EGFR exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Ivesa (firmonertinib) • RC108"],"overall_status":"Recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 09/07/2023","start_date":" 09/07/2023","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-04-10"},{"id":"a57663a3-200f-4a64-8df5-537b7c4835d2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04780568","created_at":"2023-12-11T17:16:35.473Z","updated_at":"2024-07-02T16:35:26.635Z","phase":"Phase 1","brief_title":"Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04780568","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" EGFR • NOTCH3","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I","tags":["EGFR • NOTCH3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • tegavivint (BC2059)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/18/2022","start_date":" 01/18/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-12-11"},{"id":"24a9df1f-6dbc-4a16-8c54-13431c420129","acronym":"EXCLAIM","url":"https://clinicaltrials.gov/study/NCT02716116","created_at":"2021-01-17T17:11:37.814Z","updated_at":"2024-07-02T16:35:32.901Z","phase":"Phase 1/2","brief_title":"A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02716116 - EXCLAIM","lead_sponsor":"Takeda","biomarkers":" HER-2","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • EGFR L861R • HER-2 exon 23 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • EGFR L861R • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Exkivity (mobocertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 334","initiation":"Initiation: 06/16/2016","start_date":" 06/16/2016","primary_txt":" Primary completion: 03/28/2025","primary_completion_date":" 03/28/2025","study_txt":" Completion: 03/28/2025","study_completion_date":" 03/28/2025","last_update_posted":"2023-10-18"},{"id":"4339bc3b-cd6e-40b5-bdb4-0ed50ce40904","acronym":"KCSG-LU15-09","url":"https://clinicaltrials.gov/study/NCT03434418","created_at":"2021-01-18T16:56:28.683Z","updated_at":"2024-07-02T16:35:33.271Z","phase":"Phase 2","brief_title":"A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations","source_id_and_acronym":"NCT03434418 - KCSG-LU15-09","lead_sponsor":"Duke University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 06/30/2018","start_date":" 06/30/2018","primary_txt":" Primary completion: 10/12/2022","primary_completion_date":" 10/12/2022","study_txt":" Completion: 10/12/2022","study_completion_date":" 10/12/2022","last_update_posted":"2023-10-17"},{"id":"ff9136f8-fa30-4801-a841-e3d1bcb767ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT05517083","created_at":"2022-08-26T13:58:51.157Z","updated_at":"2024-07-02T16:35:33.009Z","phase":"","brief_title":"Feasibility of Intratumoral Washing Fluid for Detecting EGFR Mutations in Lung Cancer","source_id_and_acronym":"NCT05517083","lead_sponsor":"Pusan National University Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR G719X • EGFR S768I","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR G719X • EGFR S768I"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2023-10-17"},{"id":"ea7b0831-aa27-4710-8ad0-16bc4a75633a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06067776","created_at":"2023-10-05T16:11:05.700Z","updated_at":"2024-07-02T16:35:34.583Z","phase":"Phase 1","brief_title":"Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer","source_id_and_acronym":"NCT06067776","lead_sponsor":"Jonathan Riess","biomarkers":" HER-2 • BRAF • ALK • MET • RET","pipe":" | ","alterations":" EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • MET amplification • EGFR T790M • RET fusion • HER-2 exon 20 insertion • ALK fusion • EGFR L861Q • RAS mutation • EGFR G719X • EGFR S768I • HER-2 exon 20 mutation • BRAF amplification • HER-2 exon 23 mutation","tags":["HER-2 • BRAF • ALK • MET • RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • MET amplification • EGFR T790M • RET fusion • HER-2 exon 20 insertion • ALK fusion • EGFR L861Q • RAS mutation • EGFR G719X • EGFR S768I • HER-2 exon 20 mutation • BRAF amplification • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Tagrisso (osimertinib) • Tukysa (tucatinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 01/01/2024","start_date":" 01/01/2024","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2023-10-05"},{"id":"fe7a5d8e-4b89-442a-960a-83aeeffb3ee8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04790409","created_at":"2021-03-10T13:54:17.167Z","updated_at":"2024-07-02T16:35:37.014Z","phase":"Phase 2","brief_title":"Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations","source_id_and_acronym":"NCT04790409","lead_sponsor":"Zhejiang Cancer Hospital","biomarkers":" PD-L1","pipe":" | ","alterations":" EGFR mutation • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719X + EGFR L861Q + EGFR S768I","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719X + EGFR L861Q + EGFR S768I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Tyvyt (sintilimab)"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 08/01/2019","start_date":" 08/01/2019","primary_txt":" Primary completion: 09/13/2023","primary_completion_date":" 09/13/2023","study_txt":" Completion: 09/13/2023","study_completion_date":" 09/13/2023","last_update_posted":"2023-09-14"},{"id":"06bce804-bede-4084-9f43-37dffac91812","acronym":"CVL009-2001","url":"https://clinicaltrials.gov/study/NCT06029816","created_at":"2023-09-08T20:10:17.441Z","updated_at":"2024-07-02T16:35:37.650Z","phase":"Phase 2","brief_title":"Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR Mutations","source_id_and_acronym":"NCT06029816 - CVL009-2001","lead_sponsor":"Convalife (Shanghai) Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 18 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 11/20/2023","start_date":" 11/20/2023","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2023-09-08"},{"id":"8a932c0d-6400-4ece-8158-addbdb376cf0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05168566","created_at":"2021-12-23T16:53:43.266Z","updated_at":"2024-07-02T16:35:47.483Z","phase":"Phase 2b","brief_title":"Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05168566","lead_sponsor":"Teligene US","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719X + EGFR S768I","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719X + EGFR S768I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sutetinib (SZMD4)"],"overall_status":"Recruiting","enrollment":" Enrollment 99","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2023-05-22"},{"id":"6785cd81-0dc9-489d-83a3-ebe2f7ac3a5d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05767892","created_at":"2023-03-14T14:01:43.213Z","updated_at":"2024-07-02T16:35:51.445Z","phase":"Phase 3","brief_title":"YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations","source_id_and_acronym":"NCT05767892","lead_sponsor":"Suzhou Puhe Pharmaceutical Technology Co., LTD","biomarkers":" HER-2","pipe":" | ","alterations":" EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • pemetrexed • PH001"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 05/01/2023","start_date":" 05/01/2023","primary_txt":" Primary completion: 07/30/2025","primary_completion_date":" 07/30/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-04-05"},{"id":"e735fe27-a0b5-4fa5-a68e-e717f2263e27","acronym":"","url":"https://clinicaltrials.gov/study/NCT05267288","created_at":"2022-03-04T15:53:32.976Z","updated_at":"2024-07-02T16:35:51.976Z","phase":"Phase 2","brief_title":"Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05267288","lead_sponsor":"Qingdao Central Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L861Q • EGFR G719X • EGFR S768I","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L861Q • EGFR G719X • EGFR S768I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Gilotrif (afatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/01/2021","start_date":" 02/01/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-03-29"},{"id":"8fe85d39-9953-455f-b568-6b583ec5f7cb","acronym":"BEVERLY","url":"https://clinicaltrials.gov/study/NCT02633189","created_at":"2021-01-18T12:48:29.284Z","updated_at":"2024-07-02T16:35:52.564Z","phase":"Phase 3","brief_title":"Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer","source_id_and_acronym":"NCT02633189 - BEVERLY","lead_sponsor":"National Cancer Institute, Naples","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR S768I • EGFR G719A • EGFR G719S • EGFR G719C","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR S768I • EGFR G719A • EGFR G719S • EGFR G719C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • erlotinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-03-24"},{"id":"32963fcb-fb18-4a7a-9153-fc3a5a7b7637","acronym":"","url":"https://clinicaltrials.gov/study/NCT05767866","created_at":"2023-03-14T14:01:42.806Z","updated_at":"2024-07-02T16:35:53.096Z","phase":"Phase 1/2","brief_title":"Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR","source_id_and_acronym":"NCT05767866","lead_sponsor":"Suzhou Puhe Pharmaceutical Technology Co., LTD","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PH001"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 03/30/2018","start_date":" 03/30/2018","primary_txt":" Primary completion: 12/30/2023","primary_completion_date":" 12/30/2023","study_txt":" Completion: 05/30/2024","study_completion_date":" 05/30/2024","last_update_posted":"2023-03-17"},{"id":"68799ef7-4ca6-42fa-afc7-d1b81bc51e00","acronym":"CAPLAND","url":"https://clinicaltrials.gov/study/NCT04811001","created_at":"2021-03-23T11:52:10.171Z","updated_at":"2024-07-02T16:35:55.090Z","phase":"Phase 2","brief_title":"Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations","source_id_and_acronym":"NCT04811001 - CAPLAND","lead_sponsor":"Fondazione Ricerca Traslazionale","biomarkers":" EGFR • HER-2 • BRAF • ALK • MET • ROS1","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • ALK rearrangement • EGFR L861Q • ALK mutation • ROS1 rearrangement • MET mutation • EGFR S768I • EGFR G719A • EGFR G719S • EGFR G719C","tags":["EGFR • HER-2 • BRAF • ALK • MET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • ALK rearrangement • EGFR L861Q • ALK mutation • ROS1 rearrangement • MET mutation • EGFR S768I • EGFR G719A • EGFR G719S • EGFR G719C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 06/12/2020","start_date":" 06/12/2020","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-02-21"},{"id":"eced6ff3-eb59-4479-abc1-1ecf256e2ffb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05445310","created_at":"2022-07-06T15:54:35.837Z","updated_at":"2024-07-02T16:35:55.397Z","phase":"Phase 2","brief_title":"Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05445310","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR L858R + EGFR S768I","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR L858R + EGFR S768I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 114","initiation":"Initiation: 08/06/2022","start_date":" 08/06/2022","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2023-02-16"},{"id":"df108a82-a267-4dee-adf2-6425e67269e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05548348","created_at":"2022-09-21T18:56:17.908Z","updated_at":"2024-07-02T16:36:03.669Z","phase":"Phase 2","brief_title":"First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation","source_id_and_acronym":"NCT05548348","lead_sponsor":"Chongqing University Cancer Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L861Q • EGFR G719X • EGFR S768I","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L861Q • EGFR G719X • EGFR S768I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/26/2022","start_date":" 09/26/2022","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2022-09-21"},{"id":"4de679b7-719f-4f8b-b845-31bb210ca7c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05507606","created_at":"2022-08-19T17:10:02.135Z","updated_at":"2024-07-02T16:36:05.128Z","phase":"Phase 2","brief_title":"Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations","source_id_and_acronym":"NCT05507606","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" EGFR • TP53","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I","tags":["EGFR • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tagrisso (osimertinib) • carboplatin • pemetrexed • Byvasda (bevacizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 08/01/2021","start_date":" 08/01/2021","primary_txt":" Primary completion: 08/01/2023","primary_completion_date":" 08/01/2023","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2022-08-19"}]